185 related articles for article (PubMed ID: 38130998)
21. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
22. HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab.
Bie L; Luo S; Li D; Wei Y; Mu Y; Chen X; Wang S; Guo P; Lu X
Curr Cancer Drug Targets; 2020; 20(9):700-709. PubMed ID: 32364078
[TBL] [Abstract][Full Text] [Related]
23. Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth.
Zhou L; Yu X; Li M; Gong G; Liu W; Li T; Zuo H; Li W; Gao F; Liu H
EBioMedicine; 2020 Jan; 51():102570. PubMed ID: 31806563
[TBL] [Abstract][Full Text] [Related]
24. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
25. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
26. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
[TBL] [Abstract][Full Text] [Related]
27. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
28. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
[TBL] [Abstract][Full Text] [Related]
29. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
30. HSP70 promotes tumor progression by stabilizing Skp2 expression in gastric cancer cells.
Lei Z; Xia X; He Q; Luo J; Xiong Y; Wang J; Tang H; Guan T; Tian Y; Xu S; Cui S
Mol Carcinog; 2021 Dec; 60(12):826-839. PubMed ID: 34499769
[TBL] [Abstract][Full Text] [Related]
31. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Ríos-Luci C; Díaz-Rodríguez E; Gandullo-Sánchez L; Díaz-Gil L; Ocaña A; Pandiella A
Cancer Lett; 2020 Feb; 470():161-169. PubMed ID: 31765734
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
33. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
34. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
[TBL] [Abstract][Full Text] [Related]
36. Transcription factor LHX9 (LIM Homeobox 9) enhances pyruvate kinase PKM2 activity to induce glycolytic metabolic reprogramming in cancer stem cells, promoting gastric cancer progression.
Zhao H; Jiang R; Feng Z; Wang X; Zhang C
J Transl Med; 2023 Nov; 21(1):833. PubMed ID: 37980488
[TBL] [Abstract][Full Text] [Related]
37. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
38. Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer.
Liang B; Wu Q; Wang Y; Shi Y; Sun F; Huang Q; Li G; Liu Y; Zhang S; Xu X; Yao G; Peng J; Zhai X; Wu J; Tan Y; Wu Z; Zhou R; Li S; Wu J; Yang M; Liao W; Shi M
Cancer Lett; 2024 Apr; 587():216702. PubMed ID: 38336288
[TBL] [Abstract][Full Text] [Related]
39. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
40. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
